Skip to main content

Epigenomics' FDA Application for Cancer Test to Get FDA Priority Review

NEW YORK (GenomeWeb News) – Epigenomics today said that the US Food and Drug Administration has accepted its premarket approval application for its colorectal cancer test and has granted the application priority review status.

The Berlin, Germany-based firm filed the PMA for its Epi proColon test in December, after successfully completing a head-to-head comparative study with fecal immunochemical test screening. The submission was the fourth and final module of the PMA.

The test is based on the Septin9 protein and has been available as a CE-marked test kit in Europe and the Middle East since 2009. In 2011, Epigenomics launched an improved version, the Epi proColon 2.0 CE.

Epigenomics previously licensed the Septin9 marker to Quest Diagnostics, which has incorporated it into its ColoVantage test.

"After the encouraging results from our final clinical trial and the completion of our PMA submission late last year, we are very pleased that the agency has filed the application and has granted the priority review status to the application," Thomas Taapken, CFO and acting CEO of Epigenomics, said in a statement. "While we await the final decision from the regulators, we continue to actively plan for commercialization."

The firm recently raised almost €5 million ($6.7 million) through a rights issue and a subsequent private placement.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.